Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients

By Rajan Suja   Stearns Sally   Lyman Gary   Carpenter William  

Breast Cancer Research and Treatment, Vol. 130, Iss. 1, 2011-11 ,pp. : 255-266

Springer Publishing Company

Access to resources Recommend Favorite

Predictors of tolerance to chemotherapy in older cancer patients - a prospective pilot study

By Extermann M.   Chen H.   Cantor A.B.   Corcoran M.B.   Meyer J.   Grendys E.   Cavanaugh D.   Antonek S.   Camarata A.   Haley W.E.   Balducci L.  

European Journal of Cancer, Vol. 38, Iss. 11, 2002-07 ,pp. : 1466-1473

Elsevier

Access to resources Recommend Favorite

Delivering optimal adjuvant chemotherapy in primary breast cancer: the role of rHuG-CSF

By Paridaens R.   Lyman G.H.   Leonard R.   Crawford J.   Bosly A.   Constenla M.   Jackisch C.   Pettengell R.   Szucs T.   on behalf of the Impact of Neutropenia in Chemotherapy European Study Group  

EJC Supplements, Vol. 1, Iss. 9, 2003-11 ,pp. : 1-12

Elsevier

Access to resources Recommend Favorite

Docetaxel and cyclophosphamide as adjuvant chemotherapy for early breast cancer: primary prophylaxis with G-CSF is required

By Lakhanpal Roopa   Stuart-Harris Robin   Chan Arlene   Kotasek Dusan   Beith Jane   Cuff Katharine   Bastick Patricia   Lee Clara  

Breast Cancer Management, Vol. 2, Iss. 5, 2013-09 ,pp. : 367-374

Future Medicine

Access to resources Recommend Favorite

Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival

By Heys Steven  

Breast Cancer Research and Treatment, Vol. 90, Iss. 2, 2005-03 ,pp. : 169-185

Springer Publishing Company

Access to resources Recommend Favorite